Nuzenio

Submit Selinexor

Submit Selinexor news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 12 latest news signals 8 publisher sources 100/100 entity strength

Latest news

Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - PR NewswirePR Newswire · Mon, 03 Aug 2026 20:05:00 GMTXpovio mulligan in endometrial cancer comes up short as Karyopharm presses on in myelofibrosis - Fierce PharmaFierce Pharma · Fri, 31 Jul 2026 14:00:00 GMTKaryopharm Therapeutics reports Phase 3 XPORT-EC-042 misses PFS; plans myelofibrosis sNDA - TradingViewTradingView · Fri, 31 Jul 2026 12:33:01 GMTKaryopharm plans selinexor-ruxolitinib combination filing for myelofibrosis accelerated approval - AllSciAllSci · Fri, 31 Jul 2026 12:29:21 GMTEyePoint Completes Enrollment of DURAVYU Phase 3 Trials for Diabetic Macular Edema - clinicaltrialvanguard.comclinicaltrialvanguard.com · Fri, 31 Jul 2026 07:37:59 GMTAbivax Clears Pre-NDA Meeting with FDA for Obefazimod in Ulcerative Colitis - clinicaltrialvanguard.comclinicaltrialvanguard.com · Fri, 31 Jul 2026 07:37:59 GMTKaryopharm to Submit Selinexor-Ruxolitinib sNDA for Myelofibrosis in August 2026 - clinicaltrialvanguard.comclinicaltrialvanguard.com · Fri, 31 Jul 2026 06:32:58 GMTKaryopharm Stock (KPTI) Crashes After Hours: Here's What's Driving the Move - TradingViewTradingView · Fri, 31 Jul 2026 05:25:00 GMT

Timeline

Mon, 03 Aug 2026 20:05:00 GMTKaryopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
Fri, 31 Jul 2026 14:00:00 GMTXpovio mulligan in endometrial cancer comes up short as Karyopharm presses on in myelofibrosis - Fierce Pharma
Fri, 31 Jul 2026 12:33:01 GMTKaryopharm Therapeutics reports Phase 3 XPORT-EC-042 misses PFS; plans myelofibrosis sNDA - TradingView
Fri, 31 Jul 2026 12:29:21 GMTKaryopharm plans selinexor-ruxolitinib combination filing for myelofibrosis accelerated approval - AllSci
Fri, 31 Jul 2026 07:37:59 GMTEyePoint Completes Enrollment of DURAVYU Phase 3 Trials for Diabetic Macular Edema - clinicaltrialvanguard.com
Fri, 31 Jul 2026 07:37:59 GMTAbivax Clears Pre-NDA Meeting with FDA for Obefazimod in Ulcerative Colitis - clinicaltrialvanguard.com

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Submit Selinexor.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

8 distinct publisher/source names are currently connected to this entity page.